The primary endpoint , the mean reduction of average daily pain at week @ compared with baseline , showed a positive dose-response relationship ( p = @ , @-sided ) ; the pair-wise comparison between the @-mg group and placebo was significant ( unadjusted p = @ , @-sided ) .